目的 采用Meta分析考察西達本胺聯(lián)合標準化療治療外周T細胞淋巴瘤的臨床療效。方法 搜索了中國知網(wǎng)、萬方、維普、Web of Science、PubMed、Cochrane Library、Embase等數(shù)據(jù)庫，檢索文獻發(fā)表時間為從數(shù)據(jù)庫建庫到2023年6月的西達本胺聯(lián)合標準化療治療外周T細胞淋巴瘤的試驗，應(yīng)用Cochrane中心提供的Revman 5.4軟件對數(shù)據(jù)進行統(tǒng)計學處理分析。結(jié)果 篩選符合標準的文獻為10篇，共494例患者。西達本胺在外周T細胞淋巴瘤治療中可顯著改善完全緩解率、客觀緩解率、1年生存率、1年無進展生存率，與標準化療間的差異具有統(tǒng)計學意義。結(jié)論 對于外周T細胞淋巴瘤患者，西達本胺聯(lián)合化療在完全緩解率、客觀緩解率、1年生存率、1年無進展生存率均優(yōu)于單純化療。

Objective To study the efficacy of chidamide combined with standard chemotherapy in treatment of peripheral T-cell lymphoma by Meta-analysis. Methods Trials of chidamide combined with standard chemotherapy in treatment of peripheral T-cell lymphoma were collected by retrieval from CNKI, Wanfang, VIP, Web of Science, PubMed, Cochrane Library, Embase, etc. The search time was from the establishment to June, 2023. The data were statistical analyzed by Cochrane RevMan 5.4. Results A total of 10 literatures with a total of 494 cases. Compared with standard chemotherapy, chidamide combined with standard chemotherapy can significantly improve CR, ORR, one-year PFS, and one-year OS in treatment of peripheral T-cell lymphoma with a statistically significant difference. Conclusion Compared with standard chemotherapy, chidamide combined with standard chemotherapy has better complete response rate, objective response rate, one-year survival rate, and one-year progression free survival rate in treatment of peripheral T-cell lymphoma.

R979.1

江蘇省“六大人才高峰”高層次人才選拔培養(yǎng)計劃資助項目(WSN-019);南京市科技計劃項目(201803043);南京醫(yī)科大學研究生教育研究專項2021年度重點項目(2021YJS-ZD016)